What is the role of dose-dense therapy?

International Journal of Gynecological Cancer

Volumn 15, Issue 6 SUPPL. 3, 2005, Pages 233-240

  Van Der Burg, M E L ^a   Van Der Gaast, A ^a   Vergote, I ^b   Burger, C W ^a   Van Doorn, H C ^a   De Wit, R ^a   Stoter, G ^a   Verweij, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CARBOPLATIN PLUS GEMCITABINE; CARBOPLATIN PLUS PACLITAXEL; CISPLATIN; CISPLATIN PLUS ETOPOSIDE; CISPLATIN PLUS PACLITAXEL; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; SEROTONIN 3 ANTAGONIST; TOPOTECAN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 30744469906     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00432.x     Document Type: Review

References (28)

1. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
2. Piccart MJ, Bertelsen K, James K et al. Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-years results. J Natl Cancer Inst 2000;9:699-708.
3. Van der Burg MEL, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629-34.
4. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9: 389-93.
5. Fleming G. The treatment of choice for platinum-sensitive recurrent ovarian cancer is combination therapy. In: Chung M, ed. Am Soc Clin Oncol 2002 Educational book. Alexandria, VA. 2002:524-9.
6. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-ovar-2.2 trial. Lancet 2003;361:2099-106.
7. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin vs carboplatin in platinum sensitive recurrent ovarian cancer. Results of a Gynecological Cancer Intergroup randomized phase III trial of the AGO Ovar, the NCIC CTG and the EORTC GCG [abstract]. Proc Am Soc Clin Oncol 2004;23:449. Abstract 5005.
8. Du Bois A. Treatment of advanced ovarian cancer. Eur J Cancer 2001;37:S1-7.
9. Ozols RF, Ostchega Y, Curt G et al. High-dose carboplatin in refractory ovarian cancer. J Clin Oncol 1987;5:197-201.
10. Ten Bokkel Huinink WW, Dalesio O, Rodenhuis S et al. Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynecological Cancer Cooperative Group of the EORTC and experience at the Netherlands Cancer Institute. Semin Oncol 1992; 19(Suppl. 2):99-101.
11. Ozols RF, Ostchega Y, Myers CE et al. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985;3:1246-50.
12. Planting AST, van der Burg MEL, de Boer-Dennert M et al. Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors. Ann Oncol 1995;6:190-2.
13. Van der Burg MEL, de Wit R, van Putten WLJ et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 2002;86:19-25.
14. Meyer T, Nelstrop AE, Mahmoudi M et al. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 2001;12:1705-9.
15. Rosenberg THP. Role of weekly paclitaxel in the treatment of advanced ovarian cancer. Crit Rev Oncol Hematol 2002;27:S43-51.
16. Fennelly D, Aghajanian C, Shapiro F et al. Phase I and pharmacologic study of paclitaxel administered -weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;11:187-92.
17. Markman M, Hall J, Spitz D et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002;20:2365-2369.
18. Boruta DM, Fowler WC, Gehrig PA et al. Weekly paclitaxel infusion as salvage therapy in ovarian cancer. Cancer Invest 2003;21:675-81.
19. Kita T, Kikuchi Y, Takano M et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol 2004;92:813-8.
20. De Jongh FE, de Wit R, Verweij J et al. Dose-dense cisplatin paclitaxel: a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur J Cancer 2002;38:2005-13.
21. Neijt JP, Engelholm SA, Tuxen MK et al. Explorative phase III study of paclitaxel and cisplatin versus paclitaxel carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-92.
22. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.
23. Du Bois A, Lueck HJ, Meier W et al. Cisplatin paclitaxel vs carboplatin paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynaekologische Oncologie (AGO) Study Group Trial [abstract]. Proc Am Soc Clin Oncol 1999:356a. Abstract 1374.
24. Polee MB, Sparreboom A, Eskens FALM et al. A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. Clin Cancer Res 2004;10:1928-34.
25. Havrilsky LJ, Alvarez AA, Sayer RA et al. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol 2003;88: 51-7.
26. Sakamoto H, Idei T, Kikuchi A et al. Weekly carboplatin and paclitaxel is safe, active and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with platinum containing multi-drug chemotherapy [abstract]. Proc Am Soc Clin Oncol 2003;484. Abstract 1943.
27. Dunton DJ. Phase II study of weekly paclitaxel and weekly carboplatinum in recurrent platinum sensitive ovarian cancer [abstract]. Proc Am Soc Clin Oncol 2003; 467. Abstract 1876.
28. Watanabe Y, Nakai H, Ueda H, Hoshiai H. Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer. Gynecol Oncol 2005;96:323-9.